Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -23.70%.

  • Cumberland Pharmaceuticals' EBITDA Margin fell 505.00% to -23.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.90%, marking a year-over-year increase of 2137.00%. This contributed to the annual value of -16.99% for FY2024, which is 717.00% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its EBITDA Margin stood at -23.70% for Q3 2025, which was down 243.61% from -6.90% recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA Margin peaked at 11.03% during Q1 2025, and registered a low of -66.07% during Q4 2023.
  • Its 3-year average for EBITDA Margin is -17.21%, with a median of -17.65% in 2024.
  • In the last 5 years, Cumberland Pharmaceuticals' EBITDA Margin tumbled by 4,110bps in 2023 and then spiked by 4,841bps in 2024.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA Margin (Quarterly) stood at -52.33% in 2021, then soared by 2,737bps to -24.97% in 2022, then crashed by 4,110bps to -66.07% in 2023, then soared by 4,841bps to -17.65% in 2024, then slumped by 505bps to -23.70% in 2025.
  • Its last three reported values are -23.70% in Q3 2025, -6.90% for Q2 2025, and 11.03% during Q1 2025.